Clinical and paraclinical characterstics of COVID-19 patients, who received the primary dose and at least one booster dose of vaccine in some provinces/cities in Vietnam, 2022

Abstract

A cross-sectional study was carried out by collecting data from medical records of patients aged 18 years and older, hospitalized for acute respiratory diseases at 9 hospitals in the three regions of North, Central and South Vietnam during the period from March to December 2022. The study was conducted to compare the impact of the booster dose of COVID-19 vaccine compared to the primary dose in preventing the appearance of severe-critical clinical and paraclinical symptoms in patients. A total of 1742 medical records that met the criteria were selected for analysis. The study results showed the important role of the booster dose of COVID-19 vaccine in alleviating severe symptoms and severe-critical conditions compared to the primary dose in patients such as dyspnea (44.6% vs 53.5%, p = 0.001), drowsiness, fatigue (17.5% vs 22.5% p = 0.017), coma (2 .5% vs 4.9%, p = 0.011), oliguria/anuria (1.6% vs 5.2%, p < 0.001), multiple organ failure (1.9% vs 3.9 %, p = 0.015). In the coming time, it is necessary to continue to research, evaluate and monitor the effectiveness of vaccines as well as new variants of COVID-19 to develop vaccination plans for COVID-19 prevention and control.